Bavarian Nordic and WHO Eye Increased Mpox Vaccine Production

Danish biotech firm Bavarian Nordic is considering ramping up production of its mpox vaccine based on discussions with the WHO. CEO Paul Chaplin stated that manufacturing decisions must be made soon to meet potential demand. Talks involve the WHO, Africa CDC, and other global health entities, with a focus on local production in Africa.

Danish biotech firm Bavarian Nordic could ramp up production of its mpox vaccine even before securing orders, based on outcomes of this week's talks with the World Health Organisation, CEO Paul Chaplin told Reuters on Tuesday.

Chaplin emphasized the urgency of deciding whether to manufacture "at risk" without signed contracts, due to the time needed to switch manufacturing capacity from other vaccines to mpox. Discussions are ongoing with WHO, Gavi, Africa CDC, and individual governments.

The WHO recently declared a global health emergency over an mpox outbreak in the Democratic Republic of Congo, which has spread to neighboring countries. Talks with Africa CDC are also exploring technology transfer for local vaccine manufacturing, expected to lower costs while maintaining quality.

Chaplin noted that Bavarian Nordic is in talks to manufacture 10 million doses by 2025, with 2 million doses potentially available this year if production is shifted immediately. Shares in the company rose 19% since the WHO announcement.